NCT05994157 is a Phase 1 clinical trial of CD38-SADA:177Lu-DOTA Complex in Non-hodgkin Lymphoma, sponsored by Y-mAbs Therapeutics.

Who is sponsoring NCT05994157?

NCT05994157 is sponsored by Y-mAbs Therapeutics.

What drugs are being tested in NCT05994157?

Interventions in NCT05994157: CD38-SADA:177Lu-DOTA Complex.

What condition does NCT05994157 study?

NCT05994157 studies Non-hodgkin Lymphoma.

Is NCT05994157 still recruiting?

NCT05994157 is currently terminated. Last updated 12 March 2026.

Last reviewed 2026-03-12 · How we verify

NCT05994157

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase 1, Open-label, Dose-escalation Trial With CD38-SADA:177 Lu-DOTA Drug Complex in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma

Terminated Phase 1 Last updated 12 March 2026

What this trial tests

Phase 1 trial testing CD38-SADA:177Lu-DOTA Complex in Non-hodgkin Lymphoma in 1 participant. Terminated before completion.

Timeline

21 April 2025

Primary endpoint
15 October 2025

15 October 2025

Quick facts

Lead sponsor	Y-mAbs Therapeutics
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	1
Start date	21 April 2025
Primary completion	15 October 2025
Estimated completion	15 October 2025
Sites	6 locations across United States

Drugs / interventions tested

CD38-SADA:177Lu-DOTA Complex — full drug profile →

Conditions studied

Non-hodgkin Lymphoma — all drugs for Non-hodgkin Lymphoma →

Sponsor

Y-mAbs Therapeutics — full company profile →

Who can join

18 and older, any sex, with Non-hodgkin Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients with non-Hodgkin Lymphoma will be treated with CD38-SADA:177Lu-DOTA complex (The IMP is a two-step radioimmunotherapy, delivered as two separate products CD38-SADA and 177Lu-DOTA) to establish optimal and safe therapeutic doses and dosing schedule of CD38-SADA, and 177Lu-DOTA.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

<sup>225</sup>Ac α-Pretargeted Radioimmunotherapy of Human Epidermal Growth Factor Receptor 2-Expressing Breast Cancer.
Rinne SS, Burnes Vargas D, Seo S, Veach D, et al · · 2025 · cited 2× · PMID 40473462 · DOI 10.2967/jnumed.125.269601
Establishment of <sup>68</sup>Ga-DOTA-Based Pretargeted Radioimmunodiagnosis.
Veach DR, Burnes Vargas D, Islam B, Lee SG, et al · · 2026 · PMID 42151769 · DOI 10.1021/acs.molpharmaceut.5c01766
Immunotheranostics in Solid Tumors: Longitudinal Tracking of Human IL13Rα2 CAR-T Cells In Vivo.
Mirzaei HR, Lovibond S, Gajecki L, Qureshy S, et al · · 2026 · PMID 41469157 · DOI 10.2967/jnumed.125.271365
Antibody-Based Therapies for Peripheral T-Cell Lymphoma.
Shafagati N, Paul S, Rozati S, Sterling CH. · · 2024 · PMID 39456582 · DOI 10.3390/cancers16203489

Verify or expand the search:

Other recruiting trials for Non-hodgkin Lymphoma

Currently open trials in the same condition.

NCT06875063 — GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL · Phase 1 · recruiting
NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT06299462 — PTCy and ATG for MSD and MUD Transplants · Phase 1, PHASE2 · recruiting
NCT06393335 — Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory C · EARLY_PHASE1 · recruiting
NCT06323525 — TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma · Phase 1, PHASE2 · recruiting

Other Y-mAbs Therapeutics trials

Trials by the same sponsor.

NCT04315246 — 177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melan · Phase 1, PHASE2 · withdrawn
NCT05077423 — A Phase 1 Trial of CD33xCD3 BsAb in Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia · Phase 1 · terminated
NCT04560166 — Naxitamab and GM-CSF in Combination With IT in Patients With High-Risk Neuroblastoma · Phase 2 · terminated
NCT04167618 — 177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma · Phase 1, PHASE2 · terminated
NCT04750239 — Safety and Clinical Activity of Nivatrotamab in Relapsed/Recurrent Metastatic Small-cell Lung Cancer · Phase 1, PHASE2 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05994157 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Y-mAbs Therapeutics
Last refreshed: 12 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05994157.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing